2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Gene Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult, Animal Model
PAPER

3169 Eltrombopag added to ATG-based immunosuppression and umbilical cord blood infusion for severe aplastic anemia: An era-spanning real-world cohort

Nanxi Dong, MD, Linlin Huang Sr, MD2, Xianfu Sheng, MD3, Baodong Ye, MD, PhD4, Yu Zhang Jr, MD5
1 The First Affiliated Hospital of Zhejiang Chinese medical university, Hangzhou, China
2 The First Affiliated Hospital of Zhejiang Chinese medical university, Hangzhou, China
3 The First Affiliated Hospital of Zhejiang Chinese medical university, Hangzhou, China
4 The First Affiliated Hospital of Zhejiang Chinese medical university, Hangzhou, China
5 The First Affiliated Hospital of Zhejiang Chinese medical university, Hangzhou, China

Before thrombopoietin-receptor agonists became widely accessible in China, antithymocyte globulin (ATG)-based immunosuppressive therapy combined with unrelated umbilical cord blood (UCB) infusion was an important nontransplant treatment platform for severe aplastic anemia (SAA). Eltrombopag (EPAG) is now commonly incorporated into first-line immunosuppression, but its incremental value on the ATG-UCB platform and the contemporary contribution of UCB remain uncertain. We compared hematologic response, multilineage blood-count trajectories, survival, and recorded adverse events between ATG-UCB-EPAG and ATG-UCB treatment.
We retrospectively analyzed 63 consecutive patients treated at a single center from 2017 through 2024: 44 received ATG-UCB-EPAG and 19 received ATG-UCB. Hematologic response was classified as complete response (CR), partial response (PR), or no response (NR) at 3, 6, and 12 months using prespecified criteria. Overall response rate (ORR) was CR plus PR. Repeated absolute neutrophil count (ANC), platelet count and hemoglobin measurements from baseline through month 12 were evaluated with random-intercept mixed-effects models; platelet and ANC values were log-transformed. Group-by-time interactions assessed whether recovery trajectories differed. Overall survival (OS) was measured from UCB infusion.
Median age was 50.5 years in the ATG-UCB-EPAG group and 49.0 years in the ATG-UCB group; 61.4% and 57.9% were male, respectively. The triple-therapy cohort was treated in a later era (median treatment year, 2021 vs 2018; P<0.001) and had a lower baseline ANC (median, 1.47 vs 1.74 x 10^9/L; P=0.015), while age, sex, baseline hemoglobin, platelet count, and available UCB total nucleated-cell and CD34+ cell doses were not significantly different. At 3 months, ORR among evaluable patients was 97.6% with ATG-UCB-EPAG versus 62.5% with ATG-UCB (P=0.001); At 6 months, ORR was 83.3% versus 86.7% (P=1.000), and at 12 months it was 90.3% versus 78.6% (P=0.356). The 12-month CR rate was numerically higher with triple therapy (45.2% vs 14.3%; P=0.090). Across 12 months, platelet counts were higher overall in the ATG-UCB-EPAG group (P=0.011), but nonsignificant for ANC (P=0.056) and hemoglobin (P=0.082). At month 12, median ANC, platelet count, and hemoglobin were 2.50 x 10^9/L, 55 x 10^9/L, and 113 g/L with triple therapy versus 1.90 x 10^9/L, 41 x 10^9/L, and 81 g/L with ATG-UCB. During a median observed follow-up of 24.5 months, 5/44 and 3/19 patients died; OS did not differ (P=0.605). Recorded infection, fever, bleeding, serum sickness, and rash rates were not significantly different.
In this era-spanning real-world cohort, EPAG added to ATG-UCB was associated with a substantially higher early response rate and higher platelet levels over follow-up, without a detected increase in recorded adverse events. Longer-term response and OS differences were not statistically established. These findings benchmark the three-drug strategy against the ATG-UCB platform used before widespread EPAG adoption in China, but the retrospective design, strong treatment-era imbalance, small comparator group preclude causal attribution. Most importantly, this comparison cannot isolate the contribution of UCB in the current EPAG era. A large prospective multicenter study directly comparing ATG-EPAG with ATG-UCB-EPAG, with standardized response and recovery endpoints should now be prioritized.

Nanxi Dong, MD: No relevant conflicts of interest to declare.